Acetazolamide

Richalet, Jean‐Paul; Rivera, Maria C.; Bouchet, Patrick; Chirinos, Eduardo; Onnen, Igor; Petitjean, Olivier; Bienvenu, Annick; Lasne, Francçoise; Moutereau, Stéphane; León‐Velarde, Fabiola

doi:10.1164/rccm.200505-807oc

Cited by 106 publications

(21 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acetazolamide was discontinued at ~4300m (Pheriche), at least one day before ascending to the laboratory, to allow sufficient time (e.g., ≥48 hours) for the drug to clear participants' system prior to the first data collection session at 5050m 23,24 . Previously, pre-treatment of acetazolamide has resulted in an almost negligible difference of PASP (~2mmHg; no statistical analyses were performed) 48hours after final drug treatment when compared to individuals that received placebo treatment 25 .…”

Section: Study Participants and Designmentioning

confidence: 99%

Chemoreceptor Responsiveness at Sea Level Does Not Predict the Pulmonary Pressure Response to High Altitude

Hoiland

Foster

Donnelly

et al. 2015

Chest

View full text Add to dashboard Cite

Abstract:The hypoxic ventilatory response (HVR) at sea level (SL) is moderately predictive of the change in pulmonary artery systolic pressure (PASP) to acute normobaric hypoxia. However, because of progressive changes in the chemoreflex control of breathing and acid-base balance at high altitude (HA), HVR at SL may not predict PASP at HA. We hypothesized that resting peripheral oxyhemoglobin saturation (SpO 2 ) at HA would correlate better than HVR at SL to PASP at HA. In 20 participants at SL, we measured normobaric, isocapnic HVR (L/min·-%SpO 2 -1 ) and resting PASP using echocardiography.Both resting SpO 2 and PASP measures were repeated on day 2 (n=10), days 4-8 (n=12), and 2-3 weeks (n=8) after arrival at 5050m. These data were also collected at 5050m on life-long HA residents (Sherpa; n=21

show abstract

Section: Study Participants and Designmentioning

confidence: 99%

Chemoreceptor Responsiveness at Sea Level Does Not Predict the Pulmonary Pressure Response to High Altitude

Hoiland

Foster

Donnelly

et al. 2015

Chest

View full text Add to dashboard Cite

show abstract

“…The long-term use of respiratory stimulants, such as medroxyprogesterone [88] or acetazolamide [89-91], also improves oxygenation and polycythemia in CMS patients. Angiotensin-converting enzyme inhibitors such as enalapril may also be helpful [92,93].…”

Section: Respiratory Disorders Associated With Chronic Exposure To Himentioning

confidence: 99%

Lung disease at high altitude

Stream¹,

Luks²,

Grissom³

2009

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Large numbers of people travel to high altitudes, entering an environment of hypobaric hypoxia. Exposure to low oxygen tension leads to a series of important physiologic responses that allow individuals to tolerate these hypoxic conditions. However, in some cases hypoxia triggers maladaptive responses that lead to various forms of acute and chronic high altitude illness, such as high-altitude pulmonary edema or chronic mountain sickness. Because the respiratory system plays a critical role in these adaptive and maladaptive responses, patients with underlying lung disease may be at increased risk for complications in this environment and warrant careful evaluation before any planned sojourn to higher altitudes. In this review, we describe respiratory disorders that occur with both acute and chronic exposures to high altitudes. These disorders may occur in any individual who ascends to high altitude, regardless of his/her baseline pulmonary status. We then consider the safety of high-altitude travel in patients with various forms of underlying lung disease. The available data regarding how these patients fare in hypoxic conditions are reviewed, and recommendations are provided for management prior to and during the planned sojourn.

show abstract

“…[22] Other studies from La Paz have reported similar rates of CMS with one study measuring a rate of 5.2%. [23] In Bolivia as a whole approximately two-thirds of the population live at altitudes greater than 3000 m and CMS is deemed a considerable public health problem. Studies there have found CMS rates between 8% and 10% in the male active population in the country.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Chronic Mountain Sickness in high altitude districts of Himachal Pradesh

Sahota¹,

Panwar²

2013

Indian J Occup Environ Med

View full text Add to dashboard Cite

Introduction:Chronic Mountain Sickness (CMS) is a maladaptation condition that can affect people who reside permanently at high altitude (HA). It is characterized by polycythemia, hypoxemia and dyspnea and can be fatal. Over 140 million people live permanently at HA around the world. Unfortunately, research into CMS is lacking and accurate data on the prevalence of this condition do not exist for many regions around the world. In this study, we sought to examine prevalence rates of CMS in the Indian Himalayas, focusing on the Northern State of Himachal Pradesh.Materials and Methods:We surveyed 83 individuals (69 males) in eight towns across the HA districts of Sirmaur, Kinnaur and Lahaul and Spiti in Himachal Pradesh, India. Altitudes ranged from 2350 to 4150 m. We used an adapted Qinghai CMS scoring system to diagnose CMS. Information related to subject demographics, medical history, socioeconomic status, and geography were collected to identify risk factors for CMS. Physiologic recordings of oxygen saturation (SpO2) and pulse rate were made through pulse oximetry.Results:Overall CMS prevalence was 6.17% and mean altitude was 3281 m. At altitudes above 3000 m CMS prevalence rose to 13.73%. All cases of CMS were mild and there was a significant positive correlation between CMS scores and altitude (R = 0.784, P = 0.0213). Mean SpO2 was 90.7 ± 0.4% and mean pulse rate was 80.3 ± 1.3 bpm. SpO2 significantly correlated with altitude (R = −0.929, P < 0.001). In our study, age, gender, and tobacco use were not independent risk factors for CMS. Individuals with CMS lived at higher altitudes than their non-CMS counterparts (3736.00 ± 113.30 m vs. 3279.80 ± 69.50 m, respectively; P = 0.017).Conclusion:CMS prevalence in HA towns of the Indian Himalayas of Himachal Pradesh is 6.17% and 13.73% for towns above 3000 m. Further research is required to determine the prevalence of CMS in other regions of the world and to determine risk factors associated with CMS.

show abstract

Acetazolamide

Cited by 106 publications

References 31 publications

Chemoreceptor Responsiveness at Sea Level Does Not Predict the Pulmonary Pressure Response to High Altitude

Chemoreceptor Responsiveness at Sea Level Does Not Predict the Pulmonary Pressure Response to High Altitude

Lung disease at high altitude

Prevalence of Chronic Mountain Sickness in high altitude districts of Himachal Pradesh

Contact Info

Product

Resources

About